What We're Reading: Page 107
Industry reads hand-picked by our editors
Mar 24, 2023
-
Bloomberg
Wegovy Obesity Drug Hit Makes Novo Nordisk More Valuable Than Nestle
-
The Wall Street Journal
The Personalized Stem Cells That Could One Day Treat Parkinson’s, Heart Failure, Macular Degeneration
-
Science
Pall of suspicion: NIH’s secretive ‘China initiative’ has destroyed scores of academic careers
-
Reuters
California ruling on GSK’s Zantac litigation unsurprising, but case still weighs on shares
Mar 23, 2023
Mar 22, 2023
Mar 21, 2023
-
The Boston Globe
Boston scientists say they’re a step closer to growing human eggs in the lab
-
Grid News
The big psychedelic therapy debate: To trip or not to trip?
-
Endpoints News
‘No finding of research misconduct’: MIT ends 3.5-year review of biotech founder, professor Sasisekharan
-
Science
Polio cases in Africa linked to new oral vaccine
Mar 20, 2023
-
Financial Times
Big Pharma lobbies for slice of US chip industry tax breaks
-
NPR
California enters a contract to make its own affordable insulin
-
Reuters
Novo Nordisk’s diabetes drug Ozempic back in supply in US after months of shortage
-
BioSpace
Novartis, Biogen Scrap Gene Regulation Partnerships with Sangamo
Mar 17, 2023
Mar 16, 2023
-
The Wall Street Journal
Shortage of Last-Ditch Drug for Advanced Prostate Cancer Worries Doctors
-
Reuters
Alzheimer’s Association lobbies for Medicare coverage of Leqembi and other drugs
-
Fierce Biotech
The delisting dilemma: Why do so many biotechs face being kicked off the Nasdaq?
-
WBUR
This Mass. doctor questioned a popular pregnancy drug. Now, he’s been proven right
Previous
